These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38859787)

  • 1. Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms.
    Riffi R; Boughrara W; Chentouf A; Ilias W; Brahim NMT; Berrebbah AA; Belhoucine F
    CNS Neurol Disord Drug Targets; 2024; 23(12):1463-1473. PubMed ID: 38859787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
    Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
    Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
    Zhao GX; Zhang Z; Cai WK; Shen ML; Wang P; He GH
    Epilepsy Res; 2021 Jul; 173():106615. PubMed ID: 33756436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
    Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
    Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
    Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
    Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.
    Chbili C; Fathallah N; Laouani A; Nouira M; Hassine A; Ben Amor S; Ben Ammou S; Ben Salem C; Saguem S
    J Neurogenet; 2016 Mar; 30(1):16-21. PubMed ID: 27276192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
    Yun W; Zhang F; Hu C; Luo X; Xue P; Wang J; Ge Y; Meng H; Guo Y
    Epilepsy Res; 2013 Dec; 107(3):231-7. PubMed ID: 24125961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.
    Zhu X; Yun W; Sun X; Qiu F; Zhao L; Guo Y
    Pharmacogenomics; 2014; 15(15):1867-79. PubMed ID: 25495409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
    Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
    Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
    Park PW; Seo YH; Ahn JY; Kim KA; Park JY
    J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients.
    Panomvana D; Traiyawong T; Towanabut S
    J Pharm Pharm Sci; 2013; 16(4):502-10. PubMed ID: 24210059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
    Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
    Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of
    Skripka AI; Krupenin PM; Kozhanova ON; Kudryavtseva AA; Fedina LV; Akmalova KA; Bochkov PO; Sokolova AA; Napalkov DA; Sychev DA
    Drug Metab Pers Ther; 2024 Jun; 39(2):89-97. PubMed ID: 38943286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
    He XJ; Jian LY; He XL; Tang M; Wu Y; Xu YY; Sun XJ; Zhao LM
    Epilepsia; 2014 Aug; 55(8):1301-6. PubMed ID: 24861996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
    Willrich MA; Rodrigues AC; Cerda A; Genvigir FD; Arazi SS; Dorea EL; Bernik MM; Bertolami MC; Faludi A; Largura A; Baudhuin LM; Bryant SC; Hirata MH; Hirata RD
    Clin Chim Acta; 2013 Jun; 421():157-63. PubMed ID: 23501331
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Miyata-Nozaka Y; Tan HJ; Wong SW; Raymond AA; Omar H; Zain SM
    Int J Clin Pharmacol Ther; 2021 Jan; 59(1):8-16. PubMed ID: 33026315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between SCN1A polymorphism and carbamazepine responsiveness in epilepsy: A meta-analysis.
    Zhang X; Liu J; Ye J
    Epilepsy Res; 2021 Oct; 176():106627. PubMed ID: 34218210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.